BridgeMD
New treatment option for Esketamine
Official title Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study
ClinicalTrials.gov ID: NCT07247968
What this study is testing
What is Esketamine injection group (0.25 mg/kg)?
Esketamine injection group (0.25 mg/kg) is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for esketamine.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study design was a randomized, double blind, parallel controlled trial.The goal of this clinical trial is to learn if esketamine-assisted modified electroconvulsive therapy (ESK-MECT) works to treat severe depression in adolescents. It will also learn about the safety of ESK-MECT.
- Phase 1: an early, usually small safety study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 13 to 17
You may be able to join if
- Inpatients diagnosed with Major Depressive Disorder according to the International Classification of Diseases,11th Revision(ICD-11),and scheduled for...
- Aged 13 to 17 years,regardless of gender;
- Educational attainment of primary school or higher;
- Normal hearing and vision,including color perception;
- Voluntary participation in the study with signed informed consent;
You likely can't join if
- Severe cardiovascular disease,significant arrhythmias,or other cardiac conditions;
- Inability to complete the assessment scales;
- History of substance abuse;
- Received electroconvulsive therapy(ECT)within 6 months prior to the study;
- Severe cerebrovascular disease,severe hypertension,intracranial hypertension,or presence of intracranial electrodes;
- Severe allergy or contraindication to propofol or succinylcholine;
See the full eligibility criteria
- Inpatients diagnosed with Major Depressive Disorder according to the International Classification of Diseases,11th Revision(ICD-11),and scheduled for Modified Electroconvulsive Therapy(MECT);
- Aged 13 to 17 years,regardless of gender;
- Educational attainment of primary school or higher;
- Normal hearing and vision,including color perception;
- Voluntary participation in the study with signed informed consent;
- American Society of Anesthesiologists(ASA)physical status classification I-II.
- Severe cardiovascular disease,significant arrhythmias,or other cardiac conditions;
- Inability to complete the assessment scales;
- History of substance abuse;
- Received electroconvulsive therapy(ECT)within 6 months prior to the study;
- Severe cerebrovascular disease,severe hypertension,intracranial hypertension,or presence of intracranial electrodes;
- Severe allergy or contraindication to propofol or succinylcholine;
- Comorbid with other psychiatric disorders.
The study team makes the final eligibility decision.
Where it's taking place
- Chongqing, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 13 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chongqing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.